Authors' objectives: Urothelial cancer is the most common form of bladder cancer, which usually starts in the bladder lining. Treatment of urothelial cancer is often successful at first, but the cancer may return and can spread to other parts of the body. Pembrolizumab is a new drug for the treatment of urothelial cancer. It is delivered straight into the blood once every three weeks using a drip. Some studies have suggested pembrolizumab may be helpful for people who have advanced urothelial cancer after their first treatment has stopped working. If pembrolizumab is licensed for use in the UK, it could be a new treatment option for patients with advanced urothelial cancer which may improve survival when current treatments have not worked.

Project Status: Completed

Year Published: 2015

URL for published report: http://www.hsric.nihr.ac.uk/topics/pembrolizumab-keytruda-for-advanced-or-metastatic-urothelial-cancer-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)